Long-term antilipemic therapy may lead to which of the following conditions?

Long-term antilipemic therapy, which primarily involves the use of medications to lower lipid levels in the blood, can indeed lead to alterations in vitamin absorption. This is particularly relevant for fat-soluble vitamins such as A, D, E, and K. These vitamins require dietary fats for proper absorption, and since antilipemic agents work by reducing the levels of lipids in the bloodstream, they can inadvertently interfere with the absorption of these essential vitamins from the gastrointestinal tract.

The connection between lipid levels and vitamin absorption is critical to understand since low levels of fat in the intestines can result in inadequate uptake of these vitamins, potentially leading to various deficiencies and their associated health issues. Thus, long-term management with antilipemic agents necessitates monitoring for any potential nutritional issues, especially concerning vitamin levels.

In this context, the other options do not accurately represent the effects of long-term antilipemic therapy. Increased appetite and improved digestion are not typically associated with antilipemic drugs, while dyslipidemia refers to abnormal lipid levels, which is contrary to the goal of antilipemic therapy.